Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
- 31 August 2008
- journal article
- review article
- Published by Elsevier BV in Nuclear Medicine and Biology
- Vol. 35, S35-S48
- https://doi.org/10.1016/j.nucmedbio.2008.05.002
Abstract
No abstract availableKeywords
This publication has 104 references indexed in Scilit:
- Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of ageEuropean Journal of Cancer, 2008
- Endocrine late effects from multi-modality treatment of neuroblastomaEuropean Journal of Cancer, 2005
- A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatinEuropean Journal of Cancer, 1995
- Meta-iodobenzylguanidine (MIBG) inhibits malate and succinate driven mitochondrial ATP synthesis in the human neuroblastoma cell line SK-N-BE(2c)European Journal of Cancer, 1995
- First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastomaEuropean Journal of Cancer, 1995
- Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: Correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expressionEuropean Journal of Cancer, 1995
- Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IVEuropean Journal of Cancer, 1995
- Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastomaEuropean Journal of Cancer, 1995
- Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastomaEuropean Journal of Cancer, 1995
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985